Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents
Graphical abstract
Section snippets
Acknowledgments
We thank Dr. Hideaki Hanaki and Dr. Hidehiro Matsui for measurement of MIC values of EM900 analogues. We also thank Ms. Akiko Nakagawa and Ms. Noriko Sato for various instrumental analyses.
References and notes (21)
- et al.
Motilide, motilin-like macrolide
- et al.
Int. J. Pharmaceut.
(1986) - et al.
Bioorg. Med. Chem. Lett.
(2006) Tetrahedron
(2006)- et al.
Antibiot. Chemother.
(1952) - et al.
Am. J. Physiol.
(1984) - et al.
J. Antibiot.
(1985) - et al.
J. Med. Chem.
(1987) - et al.
Chem. Pharm. Bull.
(1989) - et al.
Chem. Pharm. Bull.
(1989)
Cited by (49)
Prospects for macrolide therapy of asthma and COPD
2023, Advances in PharmacologyPast, present and future of macrolide therapy for chronic rhinosinusitis in Japan
2016, Auris Nasus LarynxCitation Excerpt :EM900 is a non-antibiotic erythromycin A derivative with anti-inflammatory activity. This activity was monitored using the THP-1 assay system, which examines the promotion of the differentiation of monocytes to macrophages [54]. We demonstrated that EM900 inhibits LPS-induced mucus production and neutrophil infiltration in rat nasal epithelium in vivo and suppresses TNF-α-induced mucin secretion in airway epithelial cells in vitro [55].
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes
2015, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The anti-inflammatory effects of macrolides are mediated through different mechanisms than their antibiotic effects and can be dissociated in macrolide derivatives. Several nonantibiotic macrolides that retain their anti-inflammatory/immunomodulatory effects are now in development as anti-inflammatory therapies.112,113 Macrolides could be delivered by means of inhalation to reduce any systemic effects.